{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:05:05Z","timestamp":1788635105247,"version":"build-2803163510"},"reference-count":46,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Multiple myeloma (MM) is a disease caused by the uncontrolled proliferation of clonal plasma cells in bone marrow. Extramedullary plasma cell infiltrations may occur at the time of diagnosis but usually arise during systemic disease progression. Central nervous system (CNS) plasmacytomas are extremely rare (less than 1% of patients with MM) and usually occur as a result of systemic disease progression. The frequency of extramedullary progression to CNS without simultaneous systemic progression is not known. Here, we present a challenging case in which local disease progression to CNS occurred without any signs of systemic progression. The extramedullary plasmacytoma originated from the dura mater of the brain mimicking a brain tumor. We review and discuss further treatment options that are available in such rare clinical scenarios in relation to the treatment already undertaken.<\/jats:p>","DOI":"10.3390\/biomedicines11041225","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T03:25:11Z","timestamp":1681961111000},"page":"1225","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Isolated Progression of Multiple Myeloma into the Extramedullary Plasmacytoma of Dura Mater: A Case Report and Review of the Literature"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2067-2715","authenticated-orcid":false,"given":"Agata","family":"Tyczy\u0144ska","sequence":"first","affiliation":[{"name":"Department of Hematology and Transplantology, Medical University of Gda\u0144sk, 80-214 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7548-939X","authenticated-orcid":false,"given":"Miko\u0142aj","family":"Turski","sequence":"additional","affiliation":[{"name":"Student Scientific Circle at the Department of Hematology and Transplantology, Medical University of Gda\u0144sk, 80-210 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Zarzycka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Transplantology, Medical University of Gda\u0144sk, 80-214 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0986-8936","authenticated-orcid":false,"given":"Jan Maciej","family":"Zaucha","sequence":"additional","affiliation":[{"name":"Department of Hematology and Transplantology, Medical University of Gda\u0144sk, 80-214 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3324\/haematol.2020.248518","article-title":"Multiple myeloma with central nervous system relapse","volume":"105","author":"Egan","year":"2020","journal-title":"Haematologica"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/10428190310001597964","article-title":"Myeloma of the central nervous system: Strong association with unfavorable chromosomal abnormalities and other high-risk disease features","volume":"45","author":"Fassas","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: A longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.clml.2013.11.004","article-title":"Patterns of Central Nervous System Involvement in Relapsed and Refractory Multiple Myeloma","volume":"14","author":"Abdallah","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bjh.12404","article-title":"Central nervous system multiple myeloma\u2013potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains","volume":"162","author":"Lee","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ajh.24351","article-title":"Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice","volume":"91","author":"Jurczyszyn","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.crad.2015.03.014","article-title":"Intracranial involvement by multiple myeloma","volume":"70","author":"Lasocki","year":"2015","journal-title":"Clin. Radiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s003300050192","article-title":"Solitary plasmacytomas of the occipital bone: A report of two cases","volume":"7","author":"Okamoto","year":"1997","journal-title":"Eur. Radiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug Transport across the Blood\u2013Brain Barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/bmt.2011.106","article-title":"Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma","volume":"47","author":"Chen","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.3389\/fonc.2022.934240","article-title":"Central Nervous System Myeloma and Unusual Extramedullary Localizations: Real Life Practical Guidance","volume":"12","author":"Sammartano","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3960\/jslrt.54.129","article-title":"Myelomatous Meningitis Evaluated by Multiparameter Flow Cytometry: Report of a Case and Review of the Literature","volume":"54","author":"Marini","year":"2014","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jocn.2005.02.008","article-title":"Intracranial multiple myeloma involving the dura","volume":"13","author":"Tsang","year":"2006","journal-title":"J. Clin. Neurosci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/hon.2185","article-title":"Overview of recent trends in diagnosis and management of leptomeningeal multiple myeloma","volume":"34","author":"Yellu","year":"2016","journal-title":"Hematol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00234-008-0390-x","article-title":"Intracranial involvement in plasmacytomas and multiple myeloma: A pictorial essay","volume":"50","author":"Cerase","year":"2008","journal-title":"Neuroradiology"},{"key":"ref_16","first-page":"221","article-title":"The importance of imaging techniques in the modern treatment of multiple myeloma","volume":"71","author":"Jurczyszyn","year":"2014","journal-title":"Przeglad Lek."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0609.2007.00956.x","article-title":"Central nervous system myelomatosis: Review of the literature","volume":"80","author":"Nieuwenhuizen","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjh.12414","article-title":"Central nervous system involvement with multiple myeloma: Long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents","volume":"162","author":"Chen","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3816\/CLML.2010.n.035","article-title":"Intracranial Multifocal Dural Involvement in Multiple Myeloma: Case Report and Review of the Literature","volume":"10","author":"Hwang","year":"2010","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3171\/jns.2006.104.4.608","article-title":"Dural plasmacytoma revealing multiple myeloma: Case report","volume":"104","author":"Haegelen","year":"2006","journal-title":"J. Neurosurg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1215\/15228517-2007-008","article-title":"Case study of intracerebral plasmacytoma as an initial presentation of multiple myeloma","volume":"9","author":"Wavre","year":"2007","journal-title":"Neuro-Oncology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3970169","DOI":"10.1155\/2018\/3970169","article-title":"Multiple Myeloma of the Central Nervous System: 13 Cases and Review of the Literature","volume":"2018","author":"Varga","year":"2018","journal-title":"J. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bjhh.2017.09.004","article-title":"Multiple myeloma and central nervous system involvement: Experience of a Brazilian center","volume":"40","author":"Dias","year":"2018","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.clml.2016.08.010","article-title":"Myelomatous Involvement of the Central Nervous System","volume":"16","author":"Paludo","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/10428190500032661","article-title":"Multiple myeloma involving the central nervous system: A report of two cases with unusual manifestations","volume":"46","author":"Pontikoglou","year":"2005","journal-title":"Leuk. Lymphoma"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mco.2021.2360","article-title":"IgD multiple myeloma with central nervous system involvement: A case report and literature review","volume":"15","author":"Chen","year":"2021","journal-title":"Mol. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.achaem.2015.04.005","article-title":"Zaj\u0119cie o\u015brodkowego uk\u0142adu nerwowego w przebiegu szpiczaka plazmocytowego\u2013Opis przypadku i przegl\u0105d literatury","volume":"46","author":"Jurczyszyn","year":"2015","journal-title":"Acta Haematol. Pol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00277-015-2484-y","article-title":"Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: The Greek Myeloma Study Group experience","volume":"94","author":"Katodritou","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s11060-011-0788-x","article-title":"Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: A case report","volume":"107","author":"Renfrow","year":"2012","journal-title":"J. Neurooncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s12185-009-0277-6","article-title":"The combination topotecan, temozolomide and dexamethasone associated with radiotherapy as treatment of central nervous system myeloma relapse","volume":"89","author":"Annibali","year":"2009","journal-title":"Int. J. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood.V118.21.302.302","article-title":"Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed\/Refractory Multiple Myeloma (MM)","volume":"118","author":"Richardson","year":"2011","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/1535-7163.MCT-06-0185","article-title":"Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib","volume":"5","author":"Williamson","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.leukres.2006.06.019","article-title":"Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma","volume":"31","author":"Mele","year":"2007","journal-title":"Leuk. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/bjh.14498","article-title":"Marizomib for central nervous system-multiple myeloma","volume":"177","author":"Badros","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3109\/10428194.2012.718343","article-title":"Effective treatment of pomalidomide in central nervous system myelomatosis","volume":"54","author":"Mussetti","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1600-0609.2005.00591.x","article-title":"Thalidomide for the treatment of leptomeningeal multiple myeloma","volume":"76","author":"Yutaka","year":"2006","journal-title":"Eur. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Li, Z., Qiu, Y., Personett, D., Huang, P., Edenfield, B., Katz, J., Babusis, D., Tang, Y., Shirely, M.A., and Moghaddam, M.F. (2013). Pomalidomide Shows Significant Therapeutic Activity against CNS Lymphoma with a Major Impact on the Tumor Microenvironment in Murine Models. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0071754"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1097\/HS9.0000000000000413","article-title":"Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma","volume":"4","author":"Zajec","year":"2020","journal-title":"Hemasphere"},{"key":"ref_39","first-page":"1923","article-title":"Send Orders for Reprints to reprints@benthamscience.net Central Nervous System Agents in Medicinal Chemistry Novel Agents in CNS Myeloma Treatment","volume":"14","author":"Gozzetti","year":"2014","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"854448","DOI":"10.3389\/fonc.2022.854448","article-title":"Clinical Outcomes of BCMA CAR-T Cells in a Multiple Myeloma Patient With Central Nervous System Invasion","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells Genetically Modified to Express an Anti\u2013B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/CJI.0000000000000391","article-title":"BCMA CAR-T Therapy Is Safe and Effective for Refractory\/Relapsed Multiple Myeloma With Central Nervous System Involvement","volume":"45","author":"Wang","year":"2022","journal-title":"J. Immunother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/cncr.26447","article-title":"Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients","volume":"118","author":"Gozzetti","year":"2012","journal-title":"Cancer"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/4\/1225\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:19:31Z","timestamp":1760123971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/4\/1225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["biomedicines11041225"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines11041225","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]}}}